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Lysosomal Diseases and
Neuropsychiatry: Opportunities to
Rebalance the Mind
Timothy M. Cox*†
Department of Medicine, University of Cambridge, Cambridge, United Kingdom
The brain is the physical organ of the mind but efforts to understand mental illness
within a neurobiological context have hitherto been unavailing. Mental disorders (anxiety,
depression, bipolar disorder, and schizophrenia) affect about one fifth of the population
and present an almost endless societal challenge at the frontier of human sciences.
Prodigious technological advances in functional neuroimaging and large-scale genetics
have not yet delivered the prospect of refined molecular understanding of mental illness
beyond early anatomical descriptions of brain metabolism. However, intensive clinical
phenotyping and quantitative metabolic studies using sophisticated radio-ligands in
positron-emission tomography, persistently favor the neurobiological approach. This
Perspective pursues a familiar maxim in Medicine, aptly summarized in the words
of Arthur Koestler: “Nature is generous in her senseless experiments on mankind.”
Hitherto, studies in neuropsychiatry have largely ignored rare genetic disorders
but derangements of specific components within the cerebral laboratory offer rich
opportunities for mechanistic exploration. Aberrant psychic behavior is characteristic
of many inborn errors of metabolism and although each disorder represents a universe
of its own, we are at a threshold for understanding, since contemporary genetics and
cell biology furnish abundant materials to take on the perturbing enigma of mental
derangement. A further development relates to orphan drugs with actions on defined
molecular targets: these represent new ways to study the pathogenesis of psychiatric
phenomena associated with rare diseases and in a manner not formerly possible. Here
we introduce the frontier of schizophrenia and its strong association with late-onset
Tay-Sachs disease as a paradigm to explore.
Keywords: psychiatric manifestations, schizophrenia, lysosomal diseases, sphingolipids, late-onset Tay-Sachs
disease, GM2 gangliosidoses, Thudichum, substrate-reduction therapy
INTRODUCTION
The nature of the mind and mental aberrations are unclaimed frontiers of medical science. Despite
twin studies indicating up to 80% heritability (Cardno et al., 2012) and intensive genetic studies of
common traits such as autism, schizophrenia and bipolar disorder, psychotherapeutic innovation
is stagnant. Links between genetic variants and mental health may inform rational drug design,
Frontiers in Molecular Biosciences | www.frontiersin.org 1 August 2020 | Volume 7 | Article 177
fmolb-07-00177 August 25, 2020 Time: 13:3 # 2
Cox Neuropsychiatry and Deranged Sphingolipids
but since key interactions between heredity and the psychological
environment are currently beyond our understanding (Misiak
et al., 2018), the prospects for better treatments are poor.
The brain is frequently affected by metabolic disorders
and about 2/3 of patients with lysosomal diseases have
neurodegenerative complications (Walterfang et al., 2013;
Sharma et al., 2018; Platt et al., 2019). Given the central
rôle of lysosomes in autophagy, energy-sensing and membrane
dynamics in metabolically active but long-lived neural cells
(Sharma et al., 2018; Ballabio and Bonifacino, 2020), florid
mental disturbances–in some cases indistinguishable from
classical schizophrenia–may be presenting features (Walterfang
et al., 2013). The unique biology of the lysosome offers
spectacular opportunities for therapeutic complementation and
this, combined with incentives of the orphan drug legislation
and outspoken success of several transformative therapies, has
intensified measures to seek cures (Mechler et al., 2015).
Remedies for rare diseases largely depend on the armory
of logic provided by biochemical genetics and molecular cell
biology. Specific therapies are available for several ultra-rare
lysosomal disorders with strong genetic determinants. Effective
treatment represents an innovative route to investigate complex
pathophysiology–a strategy that could apply to illnesses in which
mental health is deranged. This concept is not inimical to
research discovery, even in the days when nearly all treatments
were empirical. Once the exact mode of action of drugs was
known, pathogenesis was better understood and with this came
improved disease management – aspirin provides a simple
example (Cheng et al., 2002).
Here a single lysosomal disease is the focus of an
unconventional proposal to explore this retrospective approach
to understand psychosis – a lasting frontier on the boundary
of molecular neuroscience. The concept is simple: (1) Cerebral
activity in health or mental illness is the product of the
brain as a dynamic chemical laboratory driven by sensory
input; small-effect gene variants may be important but
their influence so far appears to be unfathomable. (2) Rare
conditions due to unitary determinants with large effects provide
opportunities for decisive scientific exploration. (3) Treatments
that engage defined molecular targets in diseases with disturbed
sanity are an opportunity to examine the biological basis
of mental health.
Psychiatric Manifestations of Metabolic
Diseases
Psychiatric disturbances are a presenting feature of some
inborn errors of metabolism but too often, identification of the
cause is delayed until long after the systemic manifestations
appear. With the move to early specialization and abbreviated
exposure to general and neuropsychiatric training, the risk of
misdiagnosis in a patient with a metabolic disease remains.
When this occurs, not only is specific treatment directed to
the metabolic defect denied, but inappropriate, even dangerous,
medication can easily be given in error. Clearly, any salutary
intervention is likely to be more effective before a permanent
derangement due to neuro-metabolic injury occurs. Since lost
opportunities for prompt treatment have dire consequences
for the patient, their family, carers and society as a whole,
awareness of unusual psychiatric manifestations or subtle
clinical signs indicating an inborn metabolic disease is of
crucial importance.
Table 1 illustrates the range of metabolic diseases associated
with either acute or sustained psychiatric manifestations but
is not a definitive list. A history of heredo-familial disease
or overt systemic features with or without frank cognitive or
neurological signs can expedite diagnosis but delays are the rule
when psychiatric manifestations occur alone. There are several
operational groups (Walterfang et al., 2013):-
(I) Diseases that present with acute and recurrent attacks
of confusion, sometimes mistaken for acute psychosis
(e.g., urea cycle and homocysteine remethylation defects,
hereditary tyrosinaemia type 1 and acute porphyrias).
These episodes often result from periodic metabolic
decompensation and overproduction of toxic metabolites.
Systemic, as well as neurological signs usually develop
during the attack.
(II) Diseases with long-standing psychiatric features
that arise in adolescence or adulthood: catatonia,
visual hallucinations–often aggravated by empirical
interventions. Homocystinurias, Wilson disease,
adrenoleukodystrophy, metachromatic leukodystrophy
and some lysosomal disorders fall into this category.
Personality and behavioral changes with delusions and
altered mood give rise to non-diagnostic psychiatric
features; schizophrenia is often suspected until cognitive
decline or systemic disease appear.
(III) Metabolic errors without overt cognitive loss that attract
immediate psychiatric attention – this includes patients
with Wilson disease, homocystinurias, cerebrotendinous
xanthomatosis, non-ketotic hyperglycinaemia,
monoamine oxidase A deficiency. Lysosomal diseases are
also included: the mannosidoses, mucopolysaccharidosis
types 3 A-D, metachromatic leukodystrophy and GM2
gangliosidosis.
While declining cognition is almost inevitable in metabolic
errors that affect the brain, several have psychiatric
manifestations only and loss of cognition is either absent
or extremely subtle. Some patients function persistently at
a high level for years, even many decades, before mental
capacity is affected.
Of the lysosomal diseases that fall into this category,
metachromatic leukodytrophy and late-onset Tay-Sachs disease
(GM2 gangliosidosis) are the best known. In metachromatic
leukodystrophy, psychotic features accompany injury to
sub-cortical white matter and fronto-temporal dementia.
Behavior is disorganized and emotional responses are
inappropriate; careful examination reveals short-term
memory loss and confabulation in a manner resembling
Korsakoff syndrome. The focus of this article is late-onset
Tay-Sachs disease, in which at least half the patients have severe
psychiatric disease.
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TABLE 1 | Inborn errors of metabolism with psychiatric features.
Disease group OMIM No. Psychiatric manifestations
Cofactors and Small Metabolites
Wilson disease 277900 Labile and irritable, antisocial behavior, wide-ranging,
obsessive-compulsiveness, psychosis
Cobalamin deficiency (CblC, or G) 277400 Disturbed behavior, visual hallucinations
Folate deficiency (e.g., of methylene tetrahydrofolate reductase) 236250 As above but catatonia reported
Lesch-Nyhan syndrome 300322 Dementia, aggression, self-mutilation
Porphyria (e.g., acute intermittent) 176000 Delusion, anxiety, mania, psychosis
Ornithine transcarbamylase deficiency (other genetic
hyperammonaemias)
311250 Episodic alienation, catatonia, delusions, psychotic outbursts;
protein aversion
Succinic semialdehyde dehydrogenase deficiency 234500 Attention deficit, hyperactivity, sleep disturbance,
obsessive-compulsions and autism
Monoamine oxidase deficiency 309850 Dementia, violence and (sexual) deviancy
Non-ketotic hyperglycinaemia 605899 Coma, agitation, behavioral difficulties
Cerebrotendinous xanthomatosis 213700 Mood changes, hallucinations
Peroxisomal Disorders
Adenoleukodsytrophy 300100 Attention deficit and disturbed behavior, fronto-temporal dementia
mimics psychosis
Lysosomal disorders
Sanfilippo disease subtypes A,B,C and D
Mucopolysaccharidosis (MPS type 3 A–D)
252900, 252920, 252930
and 252940
Hyperactivity, cognitive decline and aggression
Delayed systemic or skeletal MPS features
Hunter disease (MPS type 2) 309900 Cognitive decline, hyperactivity and aggression
Alpha-mannosidosis and β-mannosidosis 248500, 248510 Confusion, hallucinations and psychotic episodes
Niemann-Pick disease type C1 & C2 257220, 607625 Behavioral changes, attention-deficit hyperactivity disorder in
juveniles; autistic and psychotic behavior in adults
Anderson-Fabry disease 301500 Depression, mild cognitive impairment
Metachromatic leukodystrophy 250100 Attention deficit and disturbed behavior, fronto-temporal dementia
mimics psychosis
GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) 272800
268800
Depression, delusions, hallucinations, ideas of
reference–schizophrenia may antedate neurological in ˜50% adults
Representative disorders in which psychiatric manifestations occur: individual diseases are grouped operationally according to the principal biochemical abnormality.
OMIM refers to assigned numbers in Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim/).
“The Most Diversified Chemical
Laboratory of the Animal Economy”
(Thudichum, 1884)
In 1884, JLF Thudichum published A Treatise on the Chemical
Constitution of the Brain (Thudichum, 1884). A towering
genius and practicing doctor, he had laboriously purified and
characterized 140 distinct chemicals from extracts of bovine
and human brains. Among these, Thudichum named an
unusual component, an alkaloidal nitrogenous base and amino-
alcohol, sphingosin(e) – “in commemoration of the many
enigmas it presented to the inquirer.” Related constituents, e.g.,
sphingomyelin, are members of a vast array of sphingolipids
distributed throughout nature. The brain has a rich content
of sphingolipids: Tay-Sachs disease is one of 15 or so
sphingolipidoses in which their lysosomal recycling is impaired.
Tay-Sachs Disease (Desnick and
Kaback, 2001) – And References Therein
Like Johann Thudichum, Waren Tay worked in London. In
Whitechapel, 1881 Tay reported the first of several cases of
what later was termed Tay-Sachs disease. Aged 12 months,
the child had hypotonia and weakness of the neck and
limbs after the first few weeks of age without paralysis: on
ophthalmoscopy Tay, noted perifoveal pallor – the pathognomic
retinal “cherry-red spot.” By 161/2 months, the little girl was
helpless and passive; optic atrophy was established (Tay, 1881).
Without genetic screening, the autosomal recessive trait, Tay-
Sachs disease occurs in ∼1 in 3500 newborn Ashkenazi Jews;
at least 25 patients had been reported before Thudichum died
in 1901. Bernard Sachs, a neurologist in New York, noted
the disease in Ashkenazi families and conducted numerous
neuropathological studies (Sachs and Strauss, 1910). There was
no attempt to characterize the pathological lipid observed in
microscopically neurons throughout the body. Despite intensive
work, Thudichum’s rigorous chemical approach was either
unknown or ignored and unfortunately he was not well-placed
to pursue the powerful weapon of the clinical investigator –
the study of exceptions. It was only in 1942 that Ernst Klenck
identified gangliosides and the abnormality of GM2 in Tay-Sachs
disease (Desnick and Kaback, 2001).
Figures 1, 2 extensive neurological injury involving nearly
every neuron in a florid pathological process: at least 10% of the
dry weight of the enlarged brain of infants dying of Tay-Sachs
disease is due to the sialylated sphingolipid, GM2 ganglioside
(normal, < 0.1%).
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FIGURE 1 | Cranial imaging in a 5 year-old child with infantile-onset GM2 gangliosidosis. Magnetic resonance images (left to right: sagittal T1w; coronal T2w; axial
T2w FLAIR). Note the cerebral cortical and cerebellar atrophy with wide sulci and shrunken gyri; there are symmetrical diffuse white matter changes with reduced
T1w intensity and hyper-intense signals in T2w images – the latter indicating demyelination. Abnormal signal intensity is seen in basal ganglia, peducles, and brain
stem. Female infant born after normal delivery to unrelated white British parents without Ashkenazi ancestry; hypotonia noted at 7 months with cherry-red spots
observed. Tay-Sachs disease confirmed enzymatically and by molecular analysis of the HEXA gene (well-known “severe” mutation frequent in British “Celtic” patients
was identified). With scrupulous care and potentially salutary effects of a substrate-reducing agent (miglustat), the illness followed an unexpectedly protracted
course. Nonetheless, characteristic startle responses to sounds, loss of motor skills, epilepsy and episodes of aspiration pneumonia led to deterioration with a
peaceful death, aged 8 years.
The Biochemistry and Clinical Phenotype
of Infantile Tay-Sachs Disease (Desnick
and Kaback, 2001)
Tay-Sachs and the cognate Sandhoff disease, are due to
deficiencies of one or both lysosomal acid hydrolases (EC
3.2.1.52–beta-N-acetylhexosaminidase) known, respectively, as
the hexosaminidase A and B isozymes; identification of the
enzyme defects was inferred from GM2 ganglioside structure.
Mutations in HEXA, encoding the α-subunit of heteromeric
isozyme A or HEXB encoding the common β-subunit of both
isozymes, impair lysosomal recycling of GM2 ganglioside by
hexosaminidase A activity–an activity also dependent on GM2
activator protein (itself rarely affected by mutations in the
cognate GM2A gene).
Affected infants have axial hypotonia in the early months of
life. Lack of visual fixation partly due to impaired visual cortical
failure, and swallowing occur. There is loss of sight, speech
and other faculties: even today, the baby is likely to die with
seizures or aspiration pneumonia within 4 years. In this disease,
an infant who does not sit up by 6 months of age, will never
sit unaided. Sandhoff infants have an almost identical disease
of the nervous system and modest systemic manifestations due
to loss of hexosaminidase B activity toward glycosaminoglycans
and glycoproteins.
Attenuated Variants of GM2
Gangliosidosis – Tay-Sachs Disease
(Rapin et al., 1976; Johnson, 1981;
Harding et al., 1987; MacQueen et al.,
1988; Desnick and Kaback, 2001; Frey
et al., 2005; Neudorfer et al., 2005)
The most common GM2 gangliosidosis variant is infantile but
in the attenuated spectrum, juvenile and adult subtypes are
recognized. Juvenile disease typically presents at about 4 years
of age with cerebellar ataxia; dementia with loss of speech
and swallowing cause death due to aspiration or intractable
seizures by 20 years.
Late-onset or adult Tay-Sachs and Sandhoff diseases are
the paradigmatic focus of this Perspective. The former is the
best documented but the author has clinical experience of
both subtypes; when reviewed, one patient was 71 years old
(Harding et al., 1987). The disease has protean manifestations
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FIGURE 2 | Neuropathological findings in a 3 year-old patient with GM2 gangliosidosis. Light microscopic images of brain sections from a non-Jewish British infant
with biochemically confirmed classical infantile-onset Tay-Sachs disease showing, left to right, views of cerebellum (upper panels) and cerebrum, cingulate lobe,
(lower panels) with increasing magnification revealing structural neuronal disease and cell loss as indicated with “ghosts.” Extreme right hand panels show
ultrastructural features including florid lysosomal GM2 ganglioside storage pathology in a cerebellar Purkyneˇ cell at different magnifications (bars indicate,
respectively 2 µm and 500 nm). Macrocephaly with astrogliosis was present with striking cerebellar atrophy (total brain mass 1384 g, cerebellum and brain stem 113
g). Note special stains indicate the neuronal loss and disease in cerebellum and cerebral cortex associated with demyelination and axonal loss in subcortical white
matter. (Courtesy Dr. Andrew Deane, Department of Pathology, Cambridge University Hospitals).
and an expanding phenotype characteristically misdiagnosed
by neurologists and psychiatrists alike. There is progressive
impairment of gait as well as articulation in adolescence or
late childhood; while unequivocally deficient, assays that utilize
artificial fluorogenic substrates give plasma hexosaminidase A
determinations 1–10% of mean reference values (inactivating
mutations in classical Tay-Sachs disease are usually associated
with < 1%). First, reported in Ashkenazi Jews, who harbor a
widespread missense HEXA mutation, p.Gly269Ser, late-onset
Tay-Sachs disease occurs in non-Jews, and p.Gly269Ser is also
found; other HEXA variants occur and should be sought given
that expressivity in affected pedigrees in variable.
A mimic of innumerable chronic neurological conditions,
adult GM2 gangliosidosis frequently presents with anterior
motor neuron weakness and wasting affecting selected muscle
groups; ataxia and other cerebellar signs are variable. However,
dystonia (sometimes with tremor complicated by chorea),
dyskinesias, as well as neuropathy with mainly sensory or
autonomic features occur. Inevitably, inappropriate clinical
diagnoses of Friedreich’s ataxia, amyotrophic lateral sclerosis
and other motor neuron diseases with or without peripheral
neuropathy may arise. Dementia is variable and may be absent
for many decades however its onset can be heralded by
rapid dysarthria and facial grimacing. Abnormal ocular gaze,
optokinetic nystagmus and supranuclear palsy are reported
(Harding et al., 1987). Late-onset GM2 gangliosidosis should
be considered in patients with multisystem neurodegenerative
disorders, including those with adult onset. Even without an
approved treatment, missed diagnosis is usually catastrophic
because of the lost opportunities to counsel first-degree relatives.
Psychiatric Manifestations of GM2
Gangliosidosis
Florid psychiatric manifestations occur in at least half the patients
and may be the presenting feature. Mental aberrations occur
in late-onset Sandhoff disease but in the author’s experience,
these tend to be less marked than those in hexosaminidse A
deficiency alone.
The most striking mental abnormalities are indistinguishable
from classical schizophrenia and usually appear during puberty
or in late adolescence (Rosebush et al., 1995). Often intellect and
cognitive power are preserved (provided they are not confounded
by intrusive delusions) (MacQueen et al., 1988; Frey et al., 2005).
Several patterns of this cruel neuropsychiatric disorder
occur but classical hebephrenic schizophrenia with bizarre
behavior, severe personality disintegration, erratic speech,
agitation and childish quirks is well recognized. Disorganized
thinking, delusions with ideas of reference and visual and/or
auditory hallucinations, accompanied by inappropriate affect,
are distressing. Recovery may occur but recurrent psychotic
attacks erode the personality and induce severe depression.
Paranoid schizophrenia, sometimes with violent reactions,
also occurs. Neurological features may be completely absent
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for many years, although often aggravated by prescription
drugs – particularly neuroleptics is psychiatric use (see
below). Slurred speech, ataxia or cognitive impairment may
emerge but frank dementia is unusual; the speech defect
often accompanies impaired swallowing and the risk of
aspiration pneumonia.
Importance of Drug-Interactions in
Neuronopathic Lysosomal Diseases
(Johnson, 1981; MacQueen et al., 1988;
Rosebush et al., 1995; Shayman and Abe,
2013)
Patients afflicted by the late-onset forms of GM2 gangliosidosis
may show clinical deterioration when treated with psychotropic
agents (tricyclic antidepressants, anticonvulsants, sodium
valproate, and many antipsychotic drugs). Many of these drugs
are strong cationic amphiphiles with classical lysosomotropic
properties on which their psycho-pharmacological effects
depend–the lysosomal proton gradient collapses, thus
inducing phospholipidosis (Shayman and Abe, 2013). These
agents exacerbate the neurological illness and wherever
possible, they should be avoided (MacQueen et al., 1988;
Rosebush et al., 1995).
Therapeutic Opportunities in GM2
Gangliosidosis
Sachs referred to “this gravest and most fatal of all family
diseases” (Sachs and Strauss, 1910), and GM2 gangliosidosis
remains a paradigm of unmet need and opportunity at the
boundary of biopharmaceutical developments in lysosomal
diseases that include gene therapy (Mechler et al., 2015;
Cachon-Gonzalez et al., 2018; Platt et al., 2019). However, for
attenuated variants, innovation is based on clinical proof-of-
concept in the related sphingolipid disorder, Gaucher disease,
in which recycling of glucosylceramide is impaired. Here,
substrate-reduction therapy is predicated on inhibitors of
UDP-glucose: N-acylsphingosine D-glucosyltransferase, which
catalyzes the biosynthesis of β-D-glucosylceramide – precursor
of gangliosides and cognate glycosphingolipids (Merrill, 2011;
Shayman and Larsen, 2014).
Eliglustat, a potent and highly selective inhibitor (IC50 ≈25
nM) now globally approved (as Cerdelga R©), is an effective,
first-line drug in Gaucher disease (Mistry et al., 2018).
However, eliglustat cannot traverse the blood-brain barrier
and is thus unsuitable for neuronopathic forms of Gaucher
disease – or indeed GM2 gangliosidosis. Venglustat, an eliglustat
analog, is able to enter the brain. At the time of writing,
satisfactory completion of clinical 1-year phase 1/2 studies in
neuronopathic, Gaucher disease has led to an extension phase
(Schiffmann et al., 2020).
GM1, the parent ganglioside of GM2, as well as
lactosylceramide and globosides are derived from
glucosylceramide by the ordered action of glycosyltransferases
on the luminal side of the trans-Golgi network after
transmembrane “flipping” (Merrill, 2011). Thus the UDP-
glucose: N-acylsphingosine D-glucosyltransferase (cytosolic face)
is a common reaction target in Tay-Sachs/Sandhoff, Fabry and
Gaucher diseases. The therapeutic potential of venglustat as
a brain-penetrant inhibitor of glycosphingolipid biosynthesis,
immediately lends itself to exploration in late-onset Tay-
Sachs/Sandhoff diseases – a view supported by strong preclinical
findings in the genetically coherent, Sandhoff strain mouse, with
GM2 gangliosidosis: survival was increased, neuro-inflammation
and indicative biomarkers (including brain gangliosides), were
diminished (Marshall et al., 2019). These and other safety and
efficacy findings has prompted further clinical exploration of
venglustat (e.g., GBA-1-related Parkinson and Fabry disease).
In adults with late-onset GM2 gangliosidosis, venglustat should
decrease biosynthesis of β-D-glucosylceramide (and cognate
gangliosides), thereby rebalancing glycosphingolipid salvage and
breakdown. A trial to determine the efficacy, pharmacodynamics,
pharmacokinetics, and safety is imminent (ClinicalTrials.gov
Identifier: NCT04221450).
Clinical and biochemical studies (including CSF analysis)
will confirm therapeutic target engagement and provide an
opportunity for careful exploration of mental phenomena.
Should there be effects on the psychotic and neuropsychiatric
features of GM2 gangliosidosis, opportune clinical studies
may yield deeper understanding of the biological basis of
mental derangement. Further research should also address
the molecular dynamics of sphingolipids such as GM1,
GM2, GD2, and GD1a gangliosides in the brain and their
relationship to activity-dependent synaptic strengthening
and remodeling during development and memory formation
(Olsen and Færgeman, 2017).
DISCUSSION
Organic disease has been reported to account for > 5% of
patients who present with a first episode of psychosis (Johnstone
et al., 1987). Most of the metabolic conditions are set out in
Table 1 but perhaps the most alarming are those that present
with features resembling schizophrenia. In these, beyond the
dire effects of incarceration, neuroleptic drugs are likely to
exacerbate the lysosomal disturbance and with that perpetuate
the mental disturbance.
The extent to which mutant HEXA alleles or other genes
implicated in lysosomal diseases are responsible for psychiatric
disease in the general population is unknown. Initial genome-
wide association studies failed to detect the strong genetic linkage
between GBA1 variants in Parkinson disease and Lewy body
dementia – but the direct association with Gaucher disease led
to decisive studies based on detection of numerous disease-
related mutant alleles by sequencing. In other neurodegenerative
diseases, there is the strong association of heterozygous variants
of PGN, the progranulin gene with fronto-temporal dementia
and variants of GNPTAB, GNPTG, and the functionally related
NAGPA gene with non-syndromic stuttering. Since homozygous
or biallelic mutations of PGN are responsible respectively for
neuronal ceroid lipofuscinosis type 11 and for the mucolipidosis
subtypes, characterized by multiple lysosomal effects, dose
effects of heterozygous gene variants in causation of diverse
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neuropsychiatric diseases is clearly established (Huin et al.,
2020; Raza et al., 2016). The extent to which such rare
variants directly account for mental illness is emerging from
population-wide whole-genome sequencing data – a promising
approach in national health initiatives to improve diagnosis
(Walkley et al., 2010).
Among the lysosomal diseases, aberrant mental behavior also
occurs in Niemann-Pick C, MPS 2 and MPS 3 (A–D) – the
latter caused by defective heparan sulfate breakdown: in all,
ganglioside catabolism of neuronal cell membrane is impaired
and secondary accumulation of gangliosides occurs. Where the
lysosomal system is deranged, ectopic dendritogenesis, with
bulbous axonal swellings (spheroids) principally in terminal
trees are found. Electron microscopy shows amassed membrane
structures and multivesicular bodies in association with axonal
outgrowth meganeurites: these appear to alter interneuronal
connectivity and occur preferentially in the cerebellum and
thalamus, the most affected in GM2 gangliosidosis (Turro
et al., 2020). Neuronal membranes are highly enriched in
gangliosides, especially GM1 and others derived from the
precursor glucosylceramide. As yet, the biophysical constraints
exerted in their cognate lipid microdomains, which participate
in the regulation of dendritic spine dynamics and hence
memory formation, are not understood. However relevant to the
thesis here, selective deletion of UDP-glucose: N-acylsphingosine
D-glucosyltransferase in subsets of adult forebrain neurons has
been shown to improve spatial memory and overcome loss of
dendritic spines in the hippocampus of 5x familial AD mice,
which model Alzheimer disease (Herzer et al., 2018). This
tantalizing study is but one of many showing the central role
of gangliosides in synaptogenesis and a proof of concept for the
potentially salutary action of venglustat in GM2 gangliosidosis.
In the penultimate paragraph of his masterpiece written
nearly 150 years ago (Thudichum, 1884), Thudichum, discoverer
of sphingolipids and unwitting founder of the school of
biological psychiatry, explicitly stated: “great diseases of the
brain and spine, such as general paralysis, acute and chronic
mania, melancholy, and others, will all be shown to be
connected with specific chemical changes in neuroplasm. . ..”
Lysosomal diseases with disturbed ganglioside metabolism
with challenging effects on mental health, evoke this classical
work. Clinical investigation of novel brain-penetrant inhibitors
of glycosphingolipid biosynthesis offers a direct way to test
Thudichum’s assertion.
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